[{"id":"efdddd68-b037-4a5e-906c-80c7cd541d58","acronym":"DOVE","url":"https://clinicaltrials.gov/study/NCT06023862","created_at":"2023-09-05T18:12:37.255Z","updated_at":"2025-02-25T13:13:29.101Z","phase":"Phase 2","brief_title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","source_id_and_acronym":"NCT06023862 - DOVE","lead_sponsor":"Yonsei University","biomarkers":" MSI • PD-1 • WT1","pipe":"","alterations":" ","tags":["MSI • PD-1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/22/2024","start_date":" 01/22/2024","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-14"},{"id":"306e869c-78b9-4cd8-a270-29b5e1a0f57f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00179829","created_at":"2021-01-18T00:36:34.594Z","updated_at":"2025-02-25T16:50:46.222Z","phase":"Phase 2/3","brief_title":"WT1 for the Detection of Minimal Residual Disease","source_id_and_acronym":"NCT00179829","lead_sponsor":"Ann \u0026 Robert H Lurie Children's Hospital of Chicago","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/1999","start_date":" 02/01/1999","primary_txt":" Primary completion: 04/01/2006","primary_completion_date":" 04/01/2006","study_txt":" Completion: 04/01/2006","study_completion_date":" 04/01/2006","last_update_posted":"2025-02-04"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"9dd1dfec-0aa4-4556-89c3-d62638f6b981","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761914","created_at":"2021-01-18T18:29:09.264Z","updated_at":"2025-02-25T16:08:40.101Z","phase":"Phase 1/2","brief_title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","source_id_and_acronym":"NCT03761914","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" HER-2 • KRAS • PGR • WT1 • BRCA • MUC16","pipe":" | ","alterations":" HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation","tags":["HER-2 • KRAS • PGR • WT1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2024-11-19"},{"id":"06560225-2b42-48b3-bbbc-b9ae314d8a0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04040231","created_at":"2021-02-01T11:53:19.132Z","updated_at":"2024-07-02T16:34:26.088Z","phase":"Phase 1","brief_title":"Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma","source_id_and_acronym":"NCT04040231","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"84516b21-8265-457c-a480-fa67aca332aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04837196","created_at":"2021-04-08T12:52:25.748Z","updated_at":"2024-07-02T16:35:01.857Z","phase":"Phase 1/2","brief_title":"Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen","source_id_and_acronym":"NCT04837196","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • BRAF • ALK • WT1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • BRAF • ALK • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP7517"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-23"},{"id":"a72fc2d4-448d-4a6d-b94b-df003ce86195","acronym":"Immuno-MESODEC","url":"https://clinicaltrials.gov/study/NCT05765084","created_at":"2023-03-13T15:02:13.277Z","updated_at":"2024-07-02T16:35:03.321Z","phase":"Phase 1/2","brief_title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT05765084 - Immuno-MESODEC","lead_sponsor":"University Hospital, Antwerp","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"1079f78e-9ce0-445a-837c-c2dc7bc96947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275426","created_at":"2022-03-11T15:53:40.436Z","updated_at":"2024-07-02T16:35:13.985Z","phase":"Phase 2","brief_title":"A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor","source_id_and_acronym":"NCT05275426","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4","pipe":" | ","alterations":" EWSR1-WT1 fusion","tags":["WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EWSR1-WT1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • ESP-01"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2024-03-19"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"bdb1c58a-74c6-4750-9dd9-d9830096d0d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291444","created_at":"2021-01-18T16:15:39.130Z","updated_at":"2024-07-02T16:35:14.542Z","phase":"Phase 1","brief_title":"CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS","source_id_and_acronym":"NCT03291444","lead_sponsor":"Zhujiang Hospital","biomarkers":" KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA","pipe":" | ","alterations":" CD20 positive","tags":["KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/05/2018","start_date":" 05/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"04c90704-8700-4d3e-a27e-a296905600ec","acronym":"RELAX","url":"https://clinicaltrials.gov/study/NCT04330820","created_at":"2024-02-28T20:31:08.640Z","updated_at":"2024-07-02T16:35:17.236Z","phase":"Phase 1/2","brief_title":"Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)","source_id_and_acronym":"NCT04330820 - RELAX","lead_sponsor":"Technische Universität Dresden","biomarkers":" TP53 • JAK2 • RUNX1 • PDGFRB • WT1","pipe":"","alterations":" ","tags":["TP53 • JAK2 • RUNX1 • PDGFRB • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/06/2020","start_date":" 04/06/2020","primary_txt":" Primary completion: 10/11/2023","primary_completion_date":" 10/11/2023","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-02-28"},{"id":"79778409-4ae2-4e9c-aeca-2b7195069e98","acronym":"","url":"https://clinicaltrials.gov/study/NCT01995708","created_at":"2021-02-01T11:52:42.148Z","updated_at":"2024-07-02T16:35:19.997Z","phase":"Phase 1","brief_title":"CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","source_id_and_acronym":"NCT01995708","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • MAGEA3 • MAGEC1","pipe":"","alterations":" ","tags":["WT1 • MAGEA3 • MAGEC1"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 01/31/2014","start_date":" 01/31/2014","primary_txt":" Primary completion: 06/20/2022","primary_completion_date":" 06/20/2022","study_txt":" Completion: 06/20/2022","study_completion_date":" 06/20/2022","last_update_posted":"2024-02-09"},{"id":"7b20d6d4-1189-47d1-bd64-55eb31d095f7","acronym":"HAP2HCT","url":"https://clinicaltrials.gov/study/NCT03849651","created_at":"2021-01-18T19:00:01.850Z","updated_at":"2024-07-02T16:35:22.870Z","phase":"Phase 2","brief_title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT03849651 - HAP2HCT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10","pipe":" | ","alterations":" FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion","tags":["FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-19"},{"id":"343f189d-c6cb-4a8b-b082-0b802260f284","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320809","created_at":"2022-04-11T13:52:57.991Z","updated_at":"2024-07-02T16:35:31.834Z","phase":"Phase 1","brief_title":"Study of 3D189 in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05320809","lead_sponsor":"3D Medicines","biomarkers":" WT1","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-25"},{"id":"7906adea-ffc6-4844-a4f9-9ece80ef4a3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05360680","created_at":"2022-05-05T00:56:28.559Z","updated_at":"2024-07-02T16:35:35.573Z","phase":"Phase 1","brief_title":"A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers","source_id_and_acronym":"NCT05360680","lead_sponsor":"Cue Biopharma","biomarkers":" WT1 • CTLA4","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["WT1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CUE-102"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-09-27"},{"id":"30a4acbd-f8f4-47aa-83a4-218d8c5bcf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT00562640","created_at":"2021-01-18T02:03:03.547Z","updated_at":"2024-07-02T16:35:36.882Z","phase":"Phase 1","brief_title":"Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)","source_id_and_acronym":"NCT00562640","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • MUC16","pipe":"","alterations":" ","tags":["WT1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/16/2007","start_date":" 10/16/2007","primary_txt":" Primary completion: 08/03/2021","primary_completion_date":" 08/03/2021","study_txt":" Completion: 08/03/2021","study_completion_date":" 08/03/2021","last_update_posted":"2023-09-15"},{"id":"03185639-6494-4888-9d7d-ca64f80d0912","acronym":"BEACON","url":"https://clinicaltrials.gov/study/NCT03363867","created_at":"2021-01-18T16:36:09.574Z","updated_at":"2024-07-02T16:35:40.759Z","phase":"Phase 2","brief_title":"BEACON - ABC in Recurrent Platinum Resistant HGSOC","source_id_and_acronym":"NCT03363867 - BEACON","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" WT1 • MUC16 • PAX8","pipe":" | ","alterations":" WT1 positive","tags":["WT1 • MUC16 • PAX8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-07"},{"id":"9eac4268-8e45-4c25-be18-2972151ca188","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494167","created_at":"2021-01-18T12:01:22.240Z","updated_at":"2024-07-02T16:35:45.346Z","phase":"Phase 1","brief_title":"Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)","source_id_and_acronym":"NCT02494167","lead_sponsor":"Baylor College of Medicine","biomarkers":" KIT • WT1 • CD33 • ANPEP","pipe":"","alterations":" ","tags":["KIT • WT1 • CD33 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-06-19"},{"id":"bd894064-6aab-4559-82a9-5826efbdaeec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01291420","created_at":"2021-01-18T05:14:41.709Z","updated_at":"2024-07-02T16:35:48.201Z","phase":"Phase 1/2","brief_title":"Dendritic Cell Vaccination for Patients With Solid Tumors","source_id_and_acronym":"NCT01291420","lead_sponsor":"University Hospital, Antwerp","biomarkers":" HER-2 • KRAS • PGR • CD8 • WT1","pipe":" | ","alterations":" HER-2 negative • RAS wild-type • CD8 positive","tags":["HER-2 • KRAS • PGR • CD8 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • RAS wild-type • CD8 positive"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 05/03/2010","start_date":" 05/03/2010","primary_txt":" Primary completion: 04/25/2016","primary_completion_date":" 04/25/2016","study_txt":" Completion: 05/05/2018","study_completion_date":" 05/05/2018","last_update_posted":"2023-05-12"},{"id":"6cd6fea1-b47e-41c8-8a34-ff357b707a61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02737787","created_at":"2021-01-18T13:24:34.815Z","updated_at":"2024-07-02T16:35:51.110Z","phase":"Phase 1","brief_title":"A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02737787","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • MUC16 • CTAG1B","pipe":" | ","alterations":" WT1 expression • CTAG1B expression • WT1 positive","tags":["WT1 • MUC16 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • CTAG1B expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/06/2023","primary_completion_date":" 04/06/2023","study_txt":" Completion: 04/06/2023","study_completion_date":" 04/06/2023","last_update_posted":"2023-04-07"},{"id":"88795d74-ce07-42db-a37b-e34d26891eff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04809181","created_at":"2021-03-22T11:52:14.081Z","updated_at":"2024-07-02T16:35:55.126Z","phase":"Phase 2","brief_title":"Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients","source_id_and_acronym":"NCT04809181","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" WT1","pipe":" | ","alterations":" WT1 mutation","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/19/2021","start_date":" 03/19/2021","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 03/19/2026","study_completion_date":" 03/19/2026","last_update_posted":"2023-02-21"},{"id":"67668528-5408-4edc-9d86-1a1632971ecf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777943","created_at":"2021-01-18T18:41:15.452Z","updated_at":"2024-07-02T16:35:59.268Z","phase":"","brief_title":"Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis","source_id_and_acronym":"NCT03777943","lead_sponsor":"University Ghent","biomarkers":" VEGFA • MSLN • WT1 • CDH1 • ICAM1 • VCAM1","pipe":"","alterations":" ","tags":["VEGFA • MSLN • WT1 • CDH1 • ICAM1 • VCAM1"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 03/28/2022","primary_completion_date":" 03/28/2022","study_txt":" Completion: 03/28/2022","study_completion_date":" 03/28/2022","last_update_posted":"2022-12-12"},{"id":"95852f2d-c3f9-49a8-9023-dcdaab70f2d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02750891","created_at":"2021-01-18T13:28:43.111Z","updated_at":"2024-07-02T16:36:13.147Z","phase":"Phase 1/2","brief_title":"A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas","source_id_and_acronym":"NCT02750891","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" PD-L1 • WT1","pipe":" | ","alterations":" PD-L1 expression • HLA-A*24","tags":["PD-L1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2022-04-12"},{"id":"d14351b0-6a7c-4a76-937b-a44735e97526","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436252","created_at":"2021-02-01T11:52:50.145Z","updated_at":"2024-07-02T16:36:13.189Z","phase":"Phase 1/2","brief_title":"Study of DSP-7888 in Patients With Myelodysplastic Syndrome","source_id_and_acronym":"NCT02436252","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" HLA-A • WT1","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2022-04-12"}]